There is increasing interest in therapies that can be administered less frequently and/or avoid gastrointestinal irritation. The efficacy of once-yearly zoledronic acid (5 mg) in the treatment and prevention of osteoporosis has been evaluated in different patient populations. In the 3-year HORIZON-Pivotal Fracture Trial in postmenopausal women with osteoporosis, zoledronic acid reduced the risk of vertebral and hip fracture by 70% and 41%, respectively, versus placebo. The efficacy of zoledronic acid in preventing subsequent fracture in patients with a hip fracture was evaluated in the HORIZON-Recurrent Fracture Trial. New vertebral and nonvertebral fractures were significantly reduced by treatment initiated within 90 days of incident hip fracture, without evidence of delayed fracture healing. Data from a 1-year study show that a single zoledronic acid 5-mg infusion is superior to oral risedronate 5 mg/day for treatment and prevention of glucocorticoid-induced osteoporosis. Increases in bone mineral density and decreases in bone turnover markers were significantly greater with zoledronic acid than with risedronate. Two different treatment regimens of zoledronic acid were found to be more effective than placebo for prevention of bone loss in postmenopausal women and reducing markers of bone turnover after 2 years. In conclusion, zoledronic acid 5 mg once-yearly infusion has demonstrated marked efficacy in the treatment and prevention of primary and secondary osteoporosis, with a combination of fracture risk reduction and prevention of bone loss at key sites. It is the only agent shown to reduce the incidence of fracture and mortality in patients with a previous low-trauma hip fracture.
Black, D.M., Delmas, P.D., Eastell, R., Reid, I.R., Boonen, S., Cauley, J.A. et al. (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med356: 1809-1822.
2.
Black, D.M., Eastell, R., Cosman, F., Man, Z., Bucci-Rechtweg, C. and Mesenbrink, P. ( 2009) Effect of once-yearly zoledronic acid 5 mg on ‘super six’ non-vertebral fractures. Bone44(Suppl 2): S429.
3.
Boonen, S., Black, D., Sellmeyer, D., Eriksen, E.F., Bone, H. and Skag, A. ( 2008a) The skeletal response to zoledronic acid is not affected by renal impairment: results from the HORIZON-PFT study. Ann Rheum Dis67(Suppl II): 402.
4.
Boonen, S., Sellmeyer, D.E., Lippuner, K., Orlov-Morozov, A., Abrams, K., Mesenbrink, P. et al. (2008b) Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int74: 641-648.
5.
Boonen, S., Vanderschueren, D., Venken, K., Milisen, K., Delforge, M. and Haentjens, P. ( 2008c) Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance . J Intern Med264: 315-332.
6.
Boonen, S., Black, D.M., Colón-Emeric, C., Delmas, P., Eastell, R., Magaziner, J. et al. (2009) Annual treatment with zoledronic acid continues to be effective in old age. Osteoporos Int20(Suppl 1): S5-S22.
7.
Brufsky, A.M. ( 2008) Cancer treatment-induced bone loss: pathophysiology and clinical perspectives. Oncologist13: 187-195.
8.
Cohen, S., Levy, R.M., Keller, M., Boling, E., Emkey, R.D., Greenwald, M. et al. (1999) Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum42: 2309-2318.
9.
Colón-Emeric, C., Kuchibhatla, M., Pieper, C., Hawkes, W., Fredman, L., Magaziner, J. et al. (2003) The contribution of hip fracture to risk of subsequent fractures: data from two longitudinal studies. Osteoporos Int14: 879-883.
10.
Conte, P. and Guarneri, V. ( 2004) Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist9(Suppl 4): 28-37.
11.
Cramer, J.A., Amonkar, M.M., Hebborn, A. and Altman, R. ( 2005) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin21: 1453-1460.
12.
De Nijs, R.N., Jacobs, J.W., Lems, W.F., Laan, R.F., Algra, A., Huisman, A.M. et al. (2006) Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med355: 675-684.
13.
Devogelaer, J.P., Brown, J.P., Burckhardt, P., Meunier, P.J., Goemaere, S., Lippuner, K. et al. (2007) Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. Osteoporos Int18: 1211-1218.
14.
Eastell, R., Black, D.M., Boonen, S., Adami, S., Felsenberg, D., Lippuner, K. et al. (2009) Effect of once-yearly zoledronic acid 5 mg on fracture risk and change in femoral neck bone mineral density. J Clin Endocrinol Metab94: 3215-3225.
15.
Eriksen, E.F., Lyles, K.W., Colón-Emeric, C.S., Pieper, C.F., Magaziner, J.S., Adachi, J.D. et al. (2009) Antifracture efficacy and reduction of mortality in relation to timing of first dose of zoledronic acid after hip fracture. J Bone Miner Res24: 1308-1313.
16.
European Medicines Agency.Assessment report for Aclasta, Type II variation. European Medicines Agency . EMEA/H/C/000595/II/0016. (2008) Available at: www.emea.europa.eu/humandocs/PDFs/EPAR/aclasta/Aclasta-H-535-II-16-AR.pdf . Accessed 12 June 2009.
17.
Gnant, M.F., Mlineritsch, B., Luschin-Ebengreuth, G., Grampp, S., Kaessmann, H., Schmid, M. et al. (2007) Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol25: 820-828.
18.
Grbic, J.T., Landesberg, R., Lin, S.Q., Mesenbrink, P., Reid, I.R., Leung, P.C. et al. (2008) Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc139: 32-40.
19.
Huybrechts, K.F., Ishak, K.J. and Caro, J.J. ( 2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone38: 922-928.
20.
Jarrett, S.J., Conaghan, P.G., Sloan, V.S., Papanastasiou, P., Ortmann, C.E., O’Connor. et al. ( 2006) Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arthritis Rheum54: 1410-1414.
21.
Lippuner, K., Eastell, R., Reid, D.M., Bengtsson, C., Recknor, C. and Ish-Shalom, S. ( 2008) Effect of previous bisphosphonate use on response to zoledronic acid: results from the HORIZON-PFT study. Ann Rheum Dis67(Suppl II): 57.
22.
Lo, J.C., Pressman, A.R., Omar, M.A. and Ettinger, B. ( 2006) Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int17: 922-928.
23.
Lyles, K.W., Colón-Emeric, C.S., Magaziner, J.S., Adachi, J.D., Pieper, C.F., Mautalen, C. et al. (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med357: 1799-1809.
24.
Mazziotti, G., Giustina, A., Canalis, E. and Bilezikian, J.P. ( 2007) Glucocorticoid-induced osteoporosis: clinical and therapeutic aspects. Arq Bras Endocrinol Metabol51: 1404-1412.
25.
McClung, M., Recker, R., Miller, P., Fiske, D., Minkoff, J., Kriegman, A. et al. (2007) Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate . Bone41: 122-128.
26.
McClung, M.R., Miller, P., Recknor, C., Bucci-Rechtweg, C., Yu, S. and Benhamou, C.L.Efficacy and safety of zoledronic acid 5 mg in the prevention of osteoporosis in postmenopausal women with osteopenia: The HORIZON Prevention Study. (2009) Osteoporos Int20(Suppl 2): S191-S229.
27.
Michaelson, M.D., Kaufman, D.S., Lee, H., McGovern, F.J., Kantoff, P.W., Fallon, M.A. et al. (2007) Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol25: 1038-1042.
28.
Mok, C.C., Tong, K.H., To, C.H., Siu, Y.P. and Ma, K.M. ( 2008) Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial. Osteoporos Int19: 357-364.
29.
Nancollas, G.H., Tang, R., Phipps, R.J., Henneman, Z., Gulde, S., Wu, W. et al. (2006) Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone38: 617-627.
30.
Novartis Europharm Limited. (2008) Aclasta summary of product characteristicsNovartis Europharm Limited: Horsham, United Kingdom.
31.
Pfeilschifter, J. and Diel, I.J. ( 2000) Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol18: 1570-1593.
32.
Recker, R.R., Delmas, P.D., Halse, J., Reid, I.R., Boonen, S., Garcia-Hernandez, P.A. et al. (2008) Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res23: 6-16.
33.
Reid, D.M., Hughes, R.A., Laan, R.F., Sacco-Gibson, N.A., Wenderoth, D.H., Adami, S. et al. (2000) Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res15: 1006-1013.
34.
Reid, I.R., Brown, J.P., Burckhardt, P., Horowitz, Z., Richardson, P., Trechsel, U. et al. (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med346: 653-661.
35.
Reid, D.M., Delmas, P.D., Bone, H., Skag, A., Giannini, S., Lippuner, K. et al. (2008) Zoledronic acid reduces fractures and increases bone mineral density with and without concomitant osteoporosis therapy: results from the HORIZON-PFT study. Ann Rheum Dis67(Suppl II): 635.
36.
Reid, D.M., Devogelaer, J.P., Saag, K., Roux, C., Lau, C.S., Reginster, J.Y. et al. (2009) Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet373: 1253-1263.
37.
Rizzoli, R., Burlet, N., Cahall, D., Delmas, P.D., Eriksen, E.F., Felsenberg, D. et al. (2008) Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone42: 841-847.
38.
Robbins, J., Aragaki, A.K., Kooperberg, C., Watts, N., Wactawski-Wende, J., Jackson, R.D. et al. (2007) Factors associated with 5-year risk of hip fracture in postmenopausal women. JAMA298: 2389-2398.
39.
Ryg, J., Rejnmark, L., Overgaard, S., Brixen, K. and Vestergaard, P. ( 2009) Hip fracture patients at risk of second hip fracture: a nationwide population-based cohort study of 169,145 cases during 1977-2001 . J Bone Miner Res24: 1299-1307.
40.
Saag, K., Lindsay, R., Kriegman, A., Beamer, E. and Zhou, W. ( 2007a) A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone40: 1238-1243.
41.
Saag, K.G., Shane, E., Boonen, S., Marin, F., Donley, D.W., Taylor, K.A. et al. (2007b) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med357: 2028-2039.
42.
Silverman, S. ( 2006) Adherence to medications for the treatment of osteoporosis . Rheum Dis Clin North Am32: 721-731.
43.
Siris, E.S., Harris, S.T., Rosen, C.J., Barr, C.E., Arvesen, J.N., Abbott, T.A. et al. (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc81: 1013-1022.
44.
Smith, M.R., Eastham, J., Gleason, D.M., Shasha, D., Tchekmedyian, S. and Zinner, N. ( 2003) Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol169: 2008-2012.
45.
Suzuki, K., Takeyama, S., Sakai, Y., Yamada, S. and Shinoda, H. ( 2006) Current topics in pharmacological research on bone metabolism: inhibitory effects of bisphosphonates on the differentiation and activity of osteoclasts. J Pharmacol Sci100: 189-194.
46.
US Food and Drug Administration (FDA). (2008 ) Update of safety review follow-up to the October 1, 2007 early communication about the ongoing safety review of bisphosphonates.
47.
US Food and Drug Administration (FDA). (2009 ) Drug Safety Newsletter. Volume 2, Number 2. Available at: www.fda.gov/Drugs/DrugSafety/DrugSafetyNewsletter/default.htm . Accessed 31 July 2009.
48.
Weiss, H.M., Pfaar, U., Schweitzer, A., Wiegand, H., Skerjanec, A. and Schran, H. ( 2008) Biodistribution and plasma protein binding of zoledronic acid. Drug Metab Dispos36: 2043-2049.
49.
Yood, R.A., Emani, S., Reed, J.I., Lewis, B.E., Charpentier, M. and Lydick, E. ( 2003) Compliance with pharmacologic therapy for osteoporosis . Osteoporos Int14: 965-968.
